During a period when several diagnostics firms and clinical laboratories lowered their yearly revenue projections, citing the weak national economy, Genomic Health increased its 2008 guidance this week, based on the reimbursement success and increasing adoption of its flagship Oncotype DX product.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.